Q4 2025 · 13F-HR
NEA Management Company, LLCholdings as filed
Filed 2026-02-17 · accession 0001072613-26-000191
$1.96B
Reported value
27
Positions
2025-12-31
Period end
The Brief · NEA Management Company, LLC · Q4 2025
AI · grounded in 13F
NEA Management Company, LLC closed its position in VRNA, reducing its holdings by $240.4M. The fund also exited positions in NEUEHEALTH INC and OMDA, totaling a combined reduction of approximately $26.2M. On the buy side, the fund established a new position in LONA worth $3.5M and increased its share count in CELC by 64.88%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 15102K100 | CELC | Celcuity Inc. | $352.6M | 18.0% | 3,535,561 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $311.5M | 15.9% | 2,909,956 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx, Inc. | $198.6M | 10.1% | 3,045,262 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics, Inc. | $165.5M | 8.44% | 13,222,228 | Common | SOLE |
| 805111101 | SVRA | Savara, Inc. | $147.6M | 7.52% | 24,471,264 | Common | SOLE |
| 98937L105 | ZBIO | Zenas BioPharma, Inc. | $127.9M | 6.52% | 3,523,219 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $120.6M | 6.15% | 7,692,298 | Common | SOLE |
| 55287L101 | MBX | MBX Biosciences, Inc. | $114.0M | 5.81% | 3,614,486 | Common | SOLE |
| 22266M104 | COUR | Coursera, Inc. | $94.7M | 4.83% | 12,867,769 | Common | SOLE |
| 05156V102 | AUPH | Aurinia Pharmaceuticals, Inc. | $63.3M | 3.23% | 3,969,834 | Common | SOLE |
| 38341P102 | GOSS | Gossamer Bio, Inc. | $56.1M | 2.86% | 18,093,034 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $55.5M | 2.83% | 1,058,570 | Common | SOLE |
| 68622P109 | ORIC | ORIC Pharmaceuticals, Inc. | $33.7M | 1.72% | 4,118,621 | Common | SOLE |
| 71722W107 | PHAT | Phathom Pharmaceauticals, Inc. | $32.5M | 1.66% | 1,960,169 | Common | SOLE |
| 126638105 | CVRX | CVRx, Inc. | $14.4M | 0.73% | 2,026,083 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 Pharmaceuticals, Inc. | $12.9M | 0.66% | 3,233,743 | Common | SOLE |
| 15870P307 | CSBR | Champions Oncology, Inc. | $11.8M | 0.60% | 1,713,720 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics, Inc. | $10.8M | 0.55% | 4,448,757 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $8.7M | 0.45% | 1,090,793 | Common | SOLE |
| 46124U107 | IVA | Inventiva SA | $6.8M | 0.35% | 1,462,586 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $6.6M | 0.34% | 3,568,781 | Common | SOLE |
| 81726A209 | — | Senti Biosciences, Inc. | $3.9M | 0.20% | 3,775,615 | Common | SOLE |
| 04746L203 | LONA | LeonaBio, Inc. | $3.5M | 0.18% | 464,398 | Common | SOLE |
| 87166L209 | SYBX | Synlogic, Inc. | $3.3M | 0.17% | 2,922,772 | Common | SOLE |
| 57055L206 | MRKR | Marker Therapeutics, Inc. | $2.4M | 0.12% | 1,625,678 | Common | SOLE |
| 68277Q105 | OKUR | OnKure Therapeutics, Inc. | $1.4M | 0.07% | 478,548 | Common | SOLE |
| 45175G207 | IMA | ImageneBio, Inc. | $345,035 | 0.02% | 50,005 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.